Helmholtz Gemeinschaft


Immuntherapie von Kopf-Hals-Karzinomen - Highlights des ASCO-Kongresses 2015 [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015]

Item Type:Article
Title:Immuntherapie von Kopf-Hals-Karzinomen - Highlights des ASCO-Kongresses 2015 [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015]
Creators Name:Laban, S. and Doescher, J. and Schuler, P.J. and Bullinger, L. and Brunner, C. and Veit, J.A. and Hoffmann, T.K.
Abstract:BACKGROUND: In recent years, new immunotherapeutic drugs have become available: the so-called immune checkpoint modulators. With these drugs, unprecedented treatment results have been achieved in different malignant diseases; primarily malignant melanoma, but also in various other malignomas. These achievements have revolutionized the oncologic treatment landscape. This quickly expanding research field, driven by revolutionary treatment results, has put immunotherapy in the focus of attention. OBJECTIVE: Due to rapid developments in the field of immunotherapy, this article aims at introducing, illustrating, and summarizing the field of modern immunotherapy, based on recently presented clinical data from the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2015. MATERIALS AND METHODS: The most important ASCO Meeting 2015 immunotherapy trials for head and neck squamous cell carcinoma (HNSCC) were identified, summarized, and discussed with respect to the current state of research. RESULTS: The oncologic landscape of clinical trials is currently dominated by the new immune checkpoint modulating drugs. Also for HNSCC, a variety of clinical trials and substances are under way. The current primary focus of these trials is targeting and inhibiting the programmed death 1 (PD-1) axis. Cancer immunotherapy with immune checkpoint modulating drugs seems to be independent of human papilloma virus (HPV) status. Robust predictive markers for patient selection are not yet available. CONCLUSION: Current data from clinical trials with immune checkpoint modulators are promising. In the coming years, integration of these drugs into clinical routine can be expected. With regard to the public health economic burden and potential adverse events, the identification of predictive markers for patient selection is a major task for future trials.
Keywords:Head And Neck Squamous Cell Carcinoma, Immunotherapy, Immune Checkpoint Modulation, Immunomodulation, Programmed Cell Death-1
Page Range:612-619
Date:September 2015
Official Publication:https://doi.org/10.1007/s00106-015-0054-1
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library